Article Text

Download PDFPDF

  1. Piero Ruscitti1,
  2. Paola Cipriani1,
  3. Vasiliki Liakouli1,
  4. Daniela Iacono2,
  5. Ilenia Pantano2,
  6. Giulia Maria Destro Castaniti3,
  7. Nicola Maruotti4,
  8. Domenico Paolo Emanuele Margiotta5,
  9. Licia Picciariello6,
  10. Francesco Caso7,
  11. Rosa Daniela Grembiale8,
  12. Fabiola Atzeni9,
  13. Raffaele Scarpa7,
  14. Federico Perosa6,
  15. Antonella Afeltra5,
  16. Francesco Paolo Cantatore4,
  17. Giuliana Guggino3,
  18. Francesco Ciccia2,
  19. Roberto Giacomelli1,
  1. 1University of L’Aquila, L’Aquila, Italy
  2. 2University of Campania “Luigi Vanvitelli”, Naples, Italy
  3. 3University of Palermo, Palermo, Italy
  4. 4University of Foggia, Foggia, Italy
  5. 5Campus Bio-Medico University of Rome, Rome, Italy
  6. 6University of Bari Medical School, Bari, Italy
  7. 7University Federico II Naples, Naples, Italy
  8. 8University “Magna Graecia” of Catanzaro, Catanzaro, Italy
  9. 9Messina and Milan Univ, Milan, Messina, Italy


Background The systemic inflammatory process and the “traditional” cardiovascular (CV) risk factors could synergize the enhancement of CV burden in rheumatoid arthritis (RA) [1].

Objectives To assess the occurrence and the predictive factors of subclinical and clinical atherosclerosis in patients with RA.

Methods During 2015, consecutive patients, admitted to Italian Rheumatology Units, were assessed in GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) cohort [2]. After that, patients were followed-up in a 3-year, prospective, observational study, assessing the occurrence of subclinical (carotid and/or peripheral arteries atherosclerotic lesions detected by ultrasound imaging) and clinical atherosclerosis (myocardial infarction and/or congestive heart failure and/or cerebrovascular accidents) and possible predictive factors. McNemar test was employed to assess the changes in subclinical and clinical atherosclerosis and regression analyses exploited the ORs for the occurrence of those comorbidities.

Results After 3 years of prospective follow-up, 797 patients (82.7% female, median age of 60 years, range 21-89) were assessed. We also observed a median RA duration of 8.35 years (range 0.1-35), 70.9% of patients showed rheumatoid factor and 55.7% ACPA. Among “traditional” CV risk factors, we observed that BMI was 27.21 ± 4.05, 33% of patients reported smoking habit, 49.3% were affected by high blood pressure (HBP) and 12.3% by type 2 diabetes (T2D). Corticosteroids were administered in 75.5% of patients (low dosage 66.8%), methotrexate in 86.8%, hydroxychloroquine in 28.1% and biologic DMARDs in 60.7%. The remission was reached and maintained in 42.6% of patients, during the follow-up. We recorded an increased rate of subclinical atherosclerosis (70 vs 130 patients p<0.0001) and clinical atherosclerosis (30 vs 46 patients, p<0.001), at the end of follow-up. The multivariate regression analysis showed that T2D (OR: 4.50, 95%CI:1.74-11.62, p=0.002), HBP (OR: 2.03, 95%CI:1.04-4.14, p=0.042), ACPA (OR: 2.36, 95%CI:1.19-4.69, p=0.002) and mean values of CRP during the follow-up (OR: 1.07, 95%CI: 1.03-1.14, p=0.040) were associated with subclinical atherosclerosis. Differently, the maintenance of remission was associated with a reduced risk of subclinical atherosclerosis (OR: 0.25, 95%CI: 0.11-0.56, p=0.001). The multivariate regression analysis showed that T2D was associated with clinical atherosclerosis (OR:6.21, 95%CI:2.19-17.71, p=0.001). Conversely, the maintenance of remission was associated with a reduced risk of clinical atherosclerosis (OR:0.20, 95%CI: 0.09-0.95, p=0.041).

Conclusion The maintenance of remission was strongly associated with a reduced risk of clinical and subclinical atherosclerosis in 3-year prospective follow-up. Among “traditional” CV risk factors, T2D was significantly associated with both clinical and subclinical atherosclerosis.

References [1] Nurmohamed MT, et al. Nat Rev Rheumatol. 201511:693-704

[2] Ruscitti P, et al. Medicine (Baltimore). 2017;96:e8180.

Disclosure of Interests Piero Ruscitti Grant/research support from: PFIZER INNOVARE 2018, Speakers bureau: MSD, BMS, SOBI, LILLY, PFIZER, Paola Cipriani Grant/research support from: ACTELION, Speakers bureau: ACTELION, Vasiliki Liakouli Grant/research support from: PFIZER, Speakers bureau: SANOFI, Daniela Iacono Speakers bureau: PFIZER, Ilenia Pantano: None declared, Giulia Maria Destro Castaniti: None declared, Nicola Maruotti Speakers bureau: N Maruotti has received speaker honoraria from Pfizer outside this work, Domenico Paolo Emanuele Margiotta: None declared, Licia Picciariello: None declared, Francesco Caso: None declared, Rosa Daniela Grembiale Grant/research support from: BMS, Consultant for: JANSSEN, CELGENE, Speakers bureau: PFIZER, JANSSEN, BMS, NOVARTIS, Fabiola Atzeni: None declared, Raffaele Scarpa Speakers bureau: ABBVIE, MSD, PFIZER, LILLY, JANSEEN, CELGENE, Federico Perosa Speakers bureau: OCCASIONALLY, Antonella Afeltra Grant/research support from: MSD, PFIZER, ABBVIE, ROCHE, UCB, Speakers bureau: MSD, PFIZER, BMS, ROCHE, SANOFI, Francesco Paolo Cantatore Speakers bureau: PFIZER, ROCHE, Giuliana Guggino Grant/research support from: Laborest, Pfizer, Consultant for: Novartis, Abbvie, Speakers bureau: Sandoz, Francesco Ciccia Grant/research support from: CELGENE, PFIZER, Consultant for: UCB, NOVARTIS, CELGENE, PFIZER, LILLY, Paid instructor for: UCB, NOVARTIS, CELGENE, PFIZER, LILLY, JANSSEN, Speakers bureau: UCB, NOVARTIS, CELGENE, PFIZER, LILLY, JANSSEN, ROCHE, AMGEN, Roberto Giacomelli Grant/research support from: Pfizer, Actelion, Speakers bureau: Actelion, Bristol-Myers Squibb, Merck Sharp & Dohme, Abbvie, Pfizer, Sobi, Roche

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.